Baird analyst, Brian Skorney, reiterated his Neutral rating on shares of Amgen (NASDAQ: AMGN) after initial clinical
data for AMG ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE